RBC Capital analyst Brian Abrahams reiterated a Buy rating on Karyopharm Therapeutics (NASDAQ: KPTI) yesterday and set a price target of $25. The company’s shares closed yesterday at $18.38, close to its 52-week high of $20.39.
According to TipRanks.com, Abrahams is a 5-star analyst with an average return of 12.3% and a 55.1% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics Inc, Alder Biopharmaceuticals, and Intra-Cellular Therapies.
Currently, the analyst consensus on Karyopharm Therapeutics is a Strong Buy with an average price target of $25.60, representing a 39.3% upside. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $30 price target.
.
See today’s analyst top recommended stocks >>
Based on Karyopharm Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $10 million and GAAP net loss of $38.46 million. In comparison, last year the company had a GAAP net loss of $29.39 million.
Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company, The engages in the discovery, development, and commercialization of drugs to treat cancer and other major diseases. The company intends to initiate a pivotal randomized Phase 3 study of selinexor in combination with bortezomib (Velcade) and low-dose dexamethasone (BOSTON) in patients with multiple myeloma. Karyopharm Therapeutics was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.
